How Education can serve as a catalyst for wider Biosimilar Adoption.
Even two decades after their introduction, the global adoption rate of…
Navigating the Biosimilar Landscape: What to watch out in 2024 and Beyond
The anticipated expiration of exclusivity rights for major biologics in 2022…
How we helped a Top-20 Pharma competitively position its asset in the oncology biosimilars’ space.
The challenge: Strategically positioning an asset in the oncology biosimilars…
How we collaborated with a medium-sized pharma in the oncology biosimilars space so that they could make the most out of the ESMO conference.
The Challenge: Taking away key industry insights during a large international…
How we helped a mid-size Pharma delve into the competitor landscape and support its brand strategy development.
The challenge: Βuilding an up-to-date biosimilar competitor landscape. A…
Biosimilars on the rise: they are just getting started
Biologics have revolutionized the management of previously intractable…
Biosimilars: Enhancing physician uptake in the EU
At the moment, EU physicians seem much more comfortable than their US…
The curious case of biosimilar launches in the US
The Biologics Price Competition and Innovation Act (BPCI Act) of 2009 provided…